TG Therapeutics, Inc. (TGTX) Covered Calls

TG Therapeutics, Inc. is a biopharmaceutical enterprise focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated autoimmune diseases and oncological malignancies. The company primary product portfolio and pipeline focus heavily on advanced monoclonal antibodies and targeted therapies engineered for neurological conditions, including relapsing forms of multiple sclerosis, and various hematological cancers.

You can sell covered calls on TG Therapeutics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for TGTX (prices last updated Wed 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

TG Therapeutics, Inc. operates as a specialized, commercial-stage biopharmaceutical innovator focused primarily on the development and scaling of targeted immunotherapies for autoimmune disorders. The company core operational architecture centers on the clinical translation of advanced biologics that target CD20-expressing B-cells—white blood cells central to the progression of chronic inflammatory and autoimmune conditions. By deploying glycoengineering manufacturing techniques to strip specific sugar molecules from its antibody designs, the enterprise produces low-dose therapies capable of efficient cell depletion.

The institutional framework executes its commercial and clinical strategy through its flagship neurological therapeutic asset and a supporting pipeline of targeted small molecules. Its primary revenue driver centers on an approved intravenous anti-CD20 monoclonal antibody treatment, branded as BRIUMVI, which is commercialized nationally for adults with relapsing forms of multiple sclerosis. The company clinical research divisions operate parallel tracks focused on expanding this core asset into automated subcutaneous delivery methods while progressing early-stage allogeneic cell therapies for progressive autoimmune indications.

Competitive Landscape

1. Novartis AG – This multinational pharmaceutical corporation markets a self-administered subcutaneous anti-CD20 therapy for multiple sclerosis, directly challenging the company market share within the high-volume, at-home patient injection segment.
2. Merck & Co., Inc. – This global healthcare giant develops and distributes highly targeted clinical therapies and strategic pipeline compounds across overlapping immunology and neurological disease segments, competing for institutional market presence.
3. Biogen Inc. – This specialized neuroscience enterprise manages a comprehensive portfolio of diverse multiple sclerosis therapies and oral disease-modifying treatments, competing intensively for baseline clinical neurology prescription allocations.
4. Regeneron Pharmaceuticals, Inc. – This large-scale biotechnology leader designs, manufactures, and markets advanced monoclonal antibody treatments, rivaling the firm for specialized clinical provider integration and structural antibody development pipelines.

Strategic Outlook and Innovation

Future operational growth relies heavily on scaling the market penetration of its core therapeutic asset while advancing near-term clinical milestones to unlock broader patient demographics. Medical development teams remain heavily focused on completing Phase 3 clinical evaluations for a high-concentration, subcutaneous formulation of its principal antibody. If successful, this self-administered quarterly injection framework is designed to double the company addressable multiple sclerosis market by competing directly against traditional at-home therapies.

Concurrently, the strategic roadmap centers on expanding the therapeutic footprint of its underlying portfolio beyond neurology by initiating registration-directed trials in separate autoimmune conditions, including myasthenia gravis. Management continues to fund specialized manufacturing supply lines to support initial inventory builds for its pipeline assets while allocating capital toward stock repurchase programs. By pairing strong commercial revenue growth with exploratory cell-therapy studies, the corporation aims to preserve its competitive position within the global biotechnology landscape.

Want more examples? TGT Covered Calls | TH Covered Calls